ID
Publicaties op Oncologisch.com
Enfortumab vedotin plus pembrolizumab in untreated locally gevorderd or metastatic urothelial carcinoma: 2.5-year med...
Sacituzumab govitecan in gevorderd urothelial carcinoma: TROPiCS-04, a phase III gerandomiseerde trial.
Enfortumab vedotin versus chemotherapie bij urotheelcarcinoom: EV-301 24-maanden